Context: Differentiated thyroid cancer (DTC) in thyroglossal duct cysts is uncommon. The requirement of total thyroidectomy and lymph node dissection is still controversial.
T he most common site of ectopic thyroid tissue is the thyroglossal duct. During fetal life, the embryonic thyroid descends from the floor of the pharynx to a caudal location in front of the thyroid cartilage, which follows the thyroglossal duct. In most subjects, the duct obliterates at the 7th-10th week of gestation. However, defective obliteration can occur, and cysts or sinuses can develop. A variable percentage (up to 62%) of thyroglossal duct cyst contains agglomerates of functional thyroid follicular cells in the cyst wall (1) . Thyroglossal duct cysts are frequent in clinical practice, especially in pediatric patients (2) in whom they represent the most common midline neck mass (3, 4) . The usual presentation of thyroglossal duct cyst is a painless, slow-growing, palpable midline superior neck mass. The suggested treatment of thyroglossal duct cyst is surgery by the Sistrunk technique (5) (complete excision of the cyst and the thyroglossal duct with central hyoidectomy), and cyst recurrences are rare (6) .
Thyroid cancer in thyroglossal duct cyst is uncommon (.7-1.5% of thyroglossal duct cyst examined at histology) (4, (7) (8) (9) (10) (11) (12) (13) (14) . Recently, however, a high frequency (6.5%) of incidental thyroid cancers has been reported among patients who underwent surgery for thyroglossal duct cyst (14) . These cancers are believed to originate as either primary cancers in small remnants of ectopic thyroid tissue or as metastases from primary cancers in the thyroid gland.
Because of the limited number of cases of thyroid cancer in thyroglossal duct cyst that have been described in the literature, which only included very small series from the same center, and the heterogeneity of tumor biology, there is no definite consensus on the optimal treatment of thyroid cancer in thyroglossal duct cyst. Major controversial issues concern the requirement of total thyroidectomy either simultaneously or after excision of a thyroglossal duct cyst with a histological diagnosis of malignancy (4, (7) (8) (9) (10) (11) (12) (13) (14) , the extent of nodal dissection, and the subsequent postoperative follow-up. A recent review of the literature on thyroid cancer arising in ectopic thyroid tissue in the neck concluded that management strategies should be based on individualized risk stratification (4) .
To address these questions, we carried out a retrospective study in a continuous series of 26 patients with thyroid cancer in thyroglossal duct cyst, the largest series in the same center and one of the few where all patients underwent primary or secondary total thyroidectomy. We also examined all the literature reporting at least 5 patients with thyroid cancer in the thyroglossal duct cyst. The analysis of clinical presentation, treatment, histopathological characteristics, and tumor outcome can provide useful information for the assessment of the risk stratification in these patients.
Patients and Methods
Twenty-six patients with thyroid cancer in the thyroglossal duct cyst were referred to our thyroid clinic (regional referral center for thyroid diseases and university hospital) between 1996 and 2011. Three of the 26 patients underwent presurgical evaluation and surgery in our hospital, whereas the other 23 patients were evaluated and underwent surgery in other hospitals in Sicily.
Clinical presentation, diagnostic modalities, reasons for cyst resection, surgical treatment, and outcome were reviewed in all patients. All of the histological examinations were reviewed at our Hospital Morbid Anatomy Service. One patient had received external radiotherapy (24 Gy) during childhood for acute leukemia.
Fine-needle aspiration biopsy (FNAB) of the cyst was carried out before surgery in 6 patients. One or more nodules in the thyroid gland were present in 18 of 26 patients (69.2%): the size of the thyroid nodule was Յ 1.0 centimeter in 7 patients and Ͼ 1.0 centimeter in the other 11 patients. Enlarged laterocervical lymph nodes were identified before surgery in 3 patients (2 were suspicious for malignancy).
Thyroglossal duct cyst resection was carried out in all patients according to the Sistrunk technique (complete excision of the cyst and thyroglossal duct with central hyoidectomy). Simultaneous total or near-total thyroidectomy was performed in 8 of the 26 patients for concomitant thyroid nodular disease and/or suspicious FNAB of the thyroglossal duct cyst. Three of these 8 patients also underwent lymph node dissection. The other 18 patients underwent prophylactic total thyroidectomy at a subsequent time (the median delay was 1.5 months from the histological finding of thyroid cancer in the thyroglossal duct cyst). In addition, concomitant lymph node dissection was carried out in 14 of the 18 patients who underwent total thyroidectomy after a delay.
The tumors were staged according to the VII TNM edition (15): T (the extent of the primary tumor) and N (regional lymph node metastases) were determined based on the pathological data, and M (evidence of distant metastases) was based on the findings at the first postsurgical 131 I-whole-body scan ( 131 I-WBS). Staging was completed by evaluating the histotype, multifocality (number of tumor foci), and invasion of soft tissue adjacent to the cyst (extra-and intrathyroglossal duct cyst tumor) and/or to the thyroid gland (when involved). The detailed lymph node involvement (compartments I to VII) was also assessed.
After surgery, 131 I treatment (1110 -3700 MBq) was administered to all patients who met one or more of the subsequent criteria: tumor extension to soft tissues adjacent to the cyst or the thyroid gland, a multifocal tumor in the cyst, a concomitant tumor in the thyroglossal duct cyst and in the thyroid gland, and/or nodal metastases. The patients were followed up by neck ultrasound and by measurements of serum thyroglobulin (Tg), TSH, and anti-Tg antibody after either L-T 4 withdrawal or recombinant human TSH injection. Persistent/recurrent disease was defined by one or more than one of the following criteria: 1) serum Tg either under suppressive L-T 4 therapy or after TSH stimulation at detectable levels as defined on the basis of the Tg assay sensitivity used at the time of measurement; 2) evidence of suspicious lymph nodes during the neck ultrasound, confirmed by FNAB with Tg measured in the washout of the aspirate; and 3) positive posttherapeutic 131 I-WBS. In patients with persistent/recurrent disease, other imaging procedures (computed tomography, magnetic resonance imaging, bone scan, and positron emission tomography) were performed when appropriate.
Statistical analysis
Quantitative data are shown as the mean Ϯ SD, whereas numbers and percentage are provided for the qualitative data. Percentages were compared using the 2 test, and t tests were used for the continuous variables. All of the tests were 2-sided, and a P value Ͻ.05 was considered statistically significant. Statistical analyses were performed with SPSS software, version 13.0 for Windows (SPSS Inc., Chicago, Illinois).
Results
Clinical and histopathological characteristics of the 26 patients are presented in Table 1 . The mean age at diagnosis was 41.9 years in the 20 females and 38.6 years in the 6 males. Both of these values are significantly lower than the ages reported in the Thyroid Cancer Registry of Sicily: 48.5 Ϯ 14.1 in females (P ϭ .038) and 49.9 Ϯ 15.3 in males (P ϭ .027). The female:male ratio was 3.3:1 in thyroglossal duct cyst cancer patients compared with 4.3:1 in Sicily thyroid cancer patients (P ϭ .44) (16) .
Clinical presentation and preoperative assessment
In all cases, the thyroglossal duct cyst appeared as an asymptomatic midline upper-neck mass with cystic characteristics at the neck ultrasound examination. Preoperative FNAB of the cyst was only carried out in 6 patients and resulted in the cytological diagnosis of papillary thyroid cancer in 2 patients, follicular lesion in 3 patients, and a benign cystic lesion in 1 patient.
Surgery was performed for progressive thyroglossal duct cyst enlargement in 14 patients, cytological suspicion of malignancy after the FNAB in 5 patients, associated suspicious lymph nodes in 2 patients, and cosmetic reasons in 5 patients.
Thyroglossal duct cyst cancer characteristics
Twenty-three (88.5%) of the 26 thyroglossal duct cyst cancers showed a papillary histotype, whereas the other 3 cases (11.5%) were follicular. Tumor size in the thyroglossal duct cyst was Յ 1.0 centimeter (microcarcinoma) in 7 of 26 patients (27.0%) and Ͼ 1.0 centimeter in 16 of 26 cases (61.5%). Accurate size data were not available in the other 3 cases. Within the thyroglossal duct cyst, the cancer was multifocal in 1 case (3.8%), and adjacent soft tissue invasion was present in 8 cases (30.8%) ( Table 1) .
Malignant involvement of the thyroid gland
The thyroid gland was pathologically examined in all of the patients. A concomitant papillary cancer was found in 16 of 26 cases (61.5%). The mean tumor size in the thyroid was 7.3 Ϯ 5.1 millimeters, and most tumors (13 of 16, or 81.3%) were microcarcinomas. Multifocality was present in 8 of 16 patients (50.0%), and adjacent soft tissue invasion was present in 1 of 16 cases (6.2%) ( Table 1) .
Compared with concomitant cancers in the thyroglossal duct cyst, thyroid gland cancers were more frequently microcarcinomas (13 of 16 or 81.3% vs 7 of 26 or 27%; P ϭ .0012) and multifocal (8 of 16 or 50% vs 1 of 26 or 3.8%; P ϭ .0008) ( Table 1) . Cancer extension to the ad- 
Lymph node involvement
Out of 26 patients, 17 (65.4%) underwent lymph node dissection (Table 1 ) for a total of 15 dissections of central compartments, 10 dissections of lateral compartments, and 4 dissections of submental nodes ( Table 1) . The decision to perform lymph node dissection was based on intraoperative assessment in 6 cases and prophylactic neck dissection because of the histological characteristics of the cancer in the remaining patients. Nodal metastases were present in 15 of 17 of the examined patients (88.2%; Tables 1-3 ) all with papillary histotype cancers. Number and location of involved and removed neck nodes are reported in Tables 2 and 3 . Two-thirds of the patients with nodal metastases (10 of 15) had a tumor both in the thyroglossal duct cyst and in the thyroid gland. The central compartment was involved in 6 cases, all of which also had cancer in the thyroid (Tables 2 and 3) , lateral compartments were involved in 10 cases, and compartment I was involved in 4 cases. In the 10 patients who had cancer only in the thyroglossal duct cyst, lymph node excision was performed in 5 cases (Table   3) . One or more lymph nodes of compartments I to IV were involved in all cases, whereas compartment VI was negative in all instances (Table 3 ). The relative prevalence of lymph node neck compartment involvement in patients with thyroid cancer in the thyroglossal duct cyst was different from papillary cancers of the thyroid where the central compartment usually is primarily involved. The difference in central or lateral lymph node metastases in thyroglossal duct cyst cancers with or without thyroid gland involvement is not significant at the Fisher exact test (P ϭ .23), possibly because of the small number of cases examined (12 thyroglossal duct cyst cancers with concomitant thyroid cancer and 4 without). Tables 2 and 3 show the clinical characteristics, histopathological characteristics and outcomes in the 23 thyroglossal duct cyst thyroid cancer patients with a papillary histotype, depending on the concomitant presence (Table  2) or absence (Table 3) of cancer in the thyroid gland.
Characteristics of thyroid cancers only in thyroglossal duct cyst compared with cancers in both thyroglossal duct cyst and the thyroid gland
The patients with cancer in both sites were older compared with patients who only had cancer in the thyroglos- sal duct cyst (the age at diagnosis was 44.9 Ϯ 7.6 vs 32.0 Ϯ 12.7, respectively; P ϭ .006) and had a larger tumor size in the thyroglossal duct cyst (20.9 mm Ϯ 10.3 vs 13.6 Ϯ 5.5, respectively), although the difference did not reach statistical significance (P ϭ .07). In addition, patients with cancer in both sites were more likely to have lymph node metastases involving more than 1 compartment. The lymph node central compartment was involved in 6 patients who had cancer in the thyroglossal duct cyst and the thyroid, whereas the central compartment was not involved in any of the patients who had cancer only in the thyroglossal duct cyst. These data suggest that in most patients the cancer first originated in the thyroglossal duct cyst. At the last follow-up visit (the median follow-up was 74.2 months, and the range was 8 -225 months), 6 (23.1%) of the 26 patients had persistent papillary cancer disease; recurrent malignant disease was limited to the cervical lymph nodes in patients 12, 17, 18, and 21 (Tables  2 and 3 ). In these patients, the affected compartments had not been dissected at the first surgery.
Postsurgical treatment and follow-up
In the other 2 patients (patients 5 and 6), the recurrent site was not identified. In both, the only marker of persistent disease was a repeatedly elevated serum Tg (range, 4.3-18.0 ng/ml) after L-T 4 withdrawal. Table 4 reports the analysis of 132 patients from the 11 series with at least 5 cases of thyroid cancer in the thyroglossal duct cyst published in the literature of the last 25 years. Mean age at diagnosis was 40.8 years, with a female:male ratio of 2.1:1. Patients with cancer only in the thyroglossal duct cyst were significantly (P ϭ .0216) younger than patients with tumor both in the thyroglossal duct cyst and in the thyroid gland. Tumor in the thyroglossal duct cyst was papillary in 93.9% of cases, and malignant involvement of the thyroid gland was found in 51 of 102 cases (50.0%) where thyroidectomy was performed, always with a papillary histotype except in 1 case. Lymph node metastases were found in 40.5% of patients, but the approach to lymph node excision was very different in different series. Persistent/recurrent disease was observed in 15% of patients at last follow-up.
Data from the literature

Discussion
Thyroid cancer in thyroglossal duct cyst is often asymptomatic and difficult to identify at ultrasound, 131 I scan, and even at FNAB, which has a low diagnostic accuracy in thyroglossal duct cyst cancer because of the frequent cystic nature of the lesions (12, 17) . Therefore, the diagnosis of thyroid cancer in the thyroglossal duct cyst in most cases is delayed and is made after surgical removal of the thyroglossal duct cyst for other reasons (19 of 26 cases in our series) (7) , when the disease is no longer limited to the thyroglossal duct cyst.
Different procedures have been suggested for the management of thyroid cancer in the thyroglossal duct cyst (4, 12, 13) because the scientific evidence is weak. In fact, only a few series with more than 10 patients have been re- ported, and the patients in the same series often receive different treatments.
Although the cyst excision with the Sistrunk technique is the well-assessed surgical procedure for thyroglossal duct cyst removal, there are no standardized criteria for thyroid gland and lymph node surgery once a cancer is incidentally found in the thyroglossal duct cyst and even when a diagnosis of malignancy in the thyroglossal duct cyst is obtained preoperatively. Some experts prefer a conservative approach and only resort to thyroidectomy when clinical or ultrasound evidence of suspicious thyroid nodules is present in the gland (8, 9) . Others suggest a more aggressive approach, with radical surgery (total thyroidectomy and nodal dissection when necessary) even in the absence of thyroid nodular disease. In addition, 131 I ablation has been suggested when a relevant thyroid remnant is present (7, 11, 13) .
A rational approach to the treatment of thyroglossal duct cyst thyroid cancer must consider both the intrinsic tumor characteristics and the extension of the disease when the diagnosis is made.
Thyroid cancers in thyroglossal duct cyst have peculiar characteristics compared with tumors in the thyroid gland. Cancers in the thyroglossal duct cyst occur at a younger age than cancers in the thyroid (approximately a decade earlier in Sicily) (16) , a finding that has already been reported (Table 4) . Moreover, the average age at diagnosis is nearly a decade younger in the patients who only have cancer in the thyroglossal duct cyst compared with patients who have cancer in both the thyroglossal duct cyst and the thyroid, a difference that has also been observed in other series (Table 4) . Data on tumor size (larger in the thyroglossal duct cyst than in the thyroid), extension to adjacent soft tissues (more frequent for cancers in the thyroglossal duct cyst), and the abnormal involvement of lymph node compartments (with the central compartment less frequently involved) are all additional elements in favor of a primary de novo origin of the cancer in the thyroglossal duct cyst and secondary extension to the thyroid. In support of the de novo hypothesis, ectopic follicular thyroid cell nests have been found in over 60% of thyroglossal duct surgical specimens (4) . Therefore, when a cancer is present in both the thyroglossal duct cyst and the thyroid, it is likely that the cancer originated in the thyroglossal duct cyst rather than being a secondary localization of a primary tumor in the thyroid gland or an independent clonal origin of multiple tumor foci with malignant disease initiating both in the thyroglossal duct cyst and in the gland. Although the latter occurrences cannot be excluded for all patients, in most cases it is reasonable to hypothesize a cascade of events with the thyroglossal duct cyst primary cancer spreading first to the closer lymph nodes (compartments I-II-III-IV) and/or to the thyroid gland, both of which need to be considered the first stations for metastases because of thyroglossal duct cyst lymphatic drainage. Cancer can then spread within the thyroid gland (multifocality) and/or to the central compartment (secondary stations).
At presentation, the extension of the malignant disease is more advanced in thyroglossal duct cyst cancers in respect to similar tumors in the thyroid gland. As mentioned, the extension to adjacent soft tissues and the spread to proximal metastasizing stations (20 of 26 cases in the pres- ent series, including the thyroid gland as a secondary cancer location) are more frequent in thyroid cancers in the thyroglossal duct cyst. This finding may indicate a greater intrinsic aggressiveness of thyroid cancers in the thyroglossal duct cyst. In addition, the presence of distant metastases in the lung, which has also been reported in 2 patients with papillary thyroid cancer in the thyroglossal duct cyst (8, 10) , is surprisingly high for the small overall number of patients that were followed up. The peculiar characteristics of these tumors may be due to the biology of thyroid follicular cells giving origin to the malignancy. When the developing thyroid migrates to its definitive location, the differentiation program of the cells that are left behind in the thyroid primordium may remain incomplete. Cancers that originate from these cells may show peculiar and more aggressive characteristics. In addition, an abnormal environment could have a detrimental influence on cancer progression because of altered interactions between thyroid cells and neighboring tissue. We observed that over 60% of the patients with cancer in the thyroglossal duct cyst also had a neoplastic involvement of the thyroid gland, which was similar to the value found in many other studies (Table 4) . Therefore, total thyroidectomy should be suggested in all cases. Because of the high risk of thyroid involvement, total thyroidectomy is warranted whether the cancer originated in the thyroglossal duct cyst or in the thyroid (analogous to the routine prophylactic central compartment [level VI] neck dissection that is suggested in patients with papillary cancer of the thyroid [Guideline R27 in Ref. 18] ). Even if no nodule is evident in the thyroid at an accurate presurgery ultrasound examination, this is not sufficient to exclude the presence of microcarcinomas and/or multiple micrometastases in the gland. In the present series, a fully negative presurgery ultrasound examination was recorded in 25% of the patients with a histologically confirmed malignant thyroid involvement. Thyroid prophylactic dissection will also allow better staging of the disease.
Another controversial issue in thyroglossal duct cyst cancers is the treatment of lymph node metastases. Lymph node involvement was present in 88.2% (15 of 17) of the patients that in our series underwent neck dissection, an observation similar to a previous study that found lymph node involvement in up to 75% of patients (13) . Although in thyroid gland cancers lateral lymph node compartment involvement is relatively rare in the absence of central compartment involvement (15-20% in 2 different series) (19, 20) , this is not the case for cancers in the thyroglossal duct cyst. In the patients with cancers in the thyroglossal duct cyst, the involvement of I-II-III-IV lymph node compartments is frequent (9 of 17, or 52.9%, in our series; see Table 1 ). We believe that this metastatic localization in lateral lymph nodes cannot be considered "skip metastases" (cancer spreading to distant nodes while closer nodes are negative) in thyroglossal duct cyst cancers. This lymph node spreading pattern, in fact, is the consequence of the peculiar anatomic situation of the thyroglossal duct cyst that can be localized at, below, or over the hyoid bone. Because of the specific lymphatic drainage pathway, cancer cells from thyroglossal duct cyst can primarily spread to the submental (level I) or to the jugular (levels II-III-IV) lymph nodes without any involvement of the central compartment (level VI), which is located further away from the thyroglossal duct cyst and behaves like a secondary station. Therefore, an accurate evaluation of all lymph node neck compartments should be carried out before surgery for thyroglossal duct cyst cancer and before thyroid surgery after a cancer has been incidentally discovered in the thyroglossal duct.
The preoperative and intraoperative search for nodal metastases at all levels (I to VI) is critical for accurate postsurgical staging and a correct therapeutic approach. Lymph node dissection is required in the presence of known or suspicious metastases, but, in the absence of clinically evident involvement, the real challenges are to define whether prophylactic nodal dissection has to be performed and which compartment should be dissected. There are no scientifically obvious answers to these questions. Several studies have indicated that sentinel lymph node biopsy can be useful for the surgical management of breast cancer and melanoma. A similar technique could be used for evaluating the nodal spread of thyroid cancer in thyroglossal duct cyst, as suggested by a recent meta-analysis that indicated that sentinel node detection can avoid prophylactic lymph node surgery in up to 57% of patients with clinically node-negative thyroid cancer (21) .
In a recent series (22) , level I was routinely dissected, and nodal metastases were found in 45% of patients with thyroglossal duct cyst cancer. All level I negative patients were also negative for II-III-IV levels. The authors conclude that level I dissection is mandatory in thyroglossal duct cyst cancer patients and that metastases at this level can predict metastases in other lymph node compartments. Similarly, the presence of positive nodes at level II-III can significantly predict metastases at level IV.
The aggressive treatment of patients with thyroglossal duct cyst thyroid cancer is still controversial on the basis of the favorable prognosis of these patients and the relatively low rate of recurrences (mainly involving the regional lymph nodes). Distant metastases (less than 2%) and disease-related death are uncommon (10, 23) . These data, however, are obtained from a small number of patients with a very heterogeneous treatment and follow-up. In our series, short-term follow-up indicated residual/recurrent disease in 23.1% of patients.
A previous study of 62 patients (5 personal and 57 from different centers) suggested that the addition of total thyroidectomy and/or initial node dissection to the Sistrunk operation did not influence overall survival (9) . That study, however, used patient survival at 5 and 10 years as the treatment efficacy endpoint. Five-or 10-year overall survival cannot be considered a reliable outcome endpoint to judge the efficacy of treatment after a short follow-up period (the median follow-up was 71 months) for differentiated thyroid cancer. Moreover, data on survival were only available in 38 of 62 patients at 5 years and in 20 patients (32.3%) at 10 years. No information was available for the large majority of the patients considered.
In conclusion, at present no solid evidence is available to understand how different treatments at presentation might change the long-term course of differentiated thyroid cancer in thyroglossal duct cyst. An important issue that needs to be resolved is whether only patients at "high risk" (older than 45 y, with a large tumor size, extension to adjacent soft tissues, and nodal or distant metastases) should undergo aggressive treatment. We believe that aggressive treatment should be offered to all patients with the thyroglossal duct cyst except when a localized microcarcinoma is incidentally found at thyroglossal duct cyst removal and no sign of thyroid nodules or lymph node involvement is present. The available data indicate that the thyroglossal duct cyst tumor extension is unpredictable in most cases and only total thyroidectomy and accurate neck lymph node examination can provide appropriate staging and limit the risk of residual/recurrent disease. After surgery, the thyroglossal duct cyst thyroid cancer should be managed according to individualized procedures based on risk stratification and the guidelines for differentiated thyroid cancers.
